TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06343402: Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 350 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT06343402 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06343402 Rescue Dossier →